Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elenbecestat in Early Alzheimer's Disease
2016-003928-23Phase 3Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease comparing Elenbecestat with Placebo (2 arms). Primary endpoint: Primary efficacy and safety endpoints (unspecified). Started Feb 2017; status: terminated.
02
Drugs
elenbecestat
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on 2016-003928-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003928-23.